Evidence map›Paper›PMID 39231973›Full record

ArticleScientific reports2024

Prognostic nomogram combining

Yalin Zhang, Yongbin Cui, Huiling Liu, Cheng Chang, Yong Yin, Ruozheng Wang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yalin Zhang *Department of Radiation Oncology, The Third Affiliated Teaching Hospital of Xinjiang Medical University, Affiliated Cancer Hospital, Urumuqi, China.
Yongbin Cui *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Huiling LiuDepartment of Radiation Oncology, Binzhou People's Hospital, Binzhou, China.
Cheng ChangDepartment of Nuclear Medicine, The Third Affiliated Teaching Hospital of Xinjiang Medical University, Affiliated Cancer Hospital, Urumuqi, China.
Yong Yin *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. yinyongsd@126.com.
Ruozheng Wang *Department of Radiation Oncology, The Third Affiliated Teaching Hospital of Xinjiang Medical University, Affiliated Cancer Hospital, Urumuqi, China. wrz8526@vip.163.com.

Funding

Science and Technology Foundation of Xinjiang Uygur AutonomousRegion No.2022E02050
6 · The paper itself

Abstract

The aim of this study was to establish and validate the precision of a novel radiomics approach that integrates 18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computed tomography (CT) scan data with clinical information to improve the prognostication of survival rates in patients diagnosed with stage III Non-Small Cell Lung Cancer (NSCLC) who are not candidates for surgery. We evaluated pretreatment

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18Lung NeoplasmsNeoplasm StagingNomogramsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsRadiomicsFluorodeoxyglucose F1818F-FDG PET/CTImmunotherapyNon-small cell lung cancerOverall surviveRadiomics

Identifiers

PMID39231973
PMCPMC11374974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.